The Latvian Medicines Industry plans to quadrate the turnover in ten years / day
The strategy of the Latvian medicinal product industry provides systemic support for strengthening drug production capacity, investment in research and innovation, and for the development of human capital.
« The Latvian pharmaceutical sector is ready to significantly increase its contribution to the national economy – from the current turnover of EUR 400 million to 1.5 billion in the next ten years. This goal requires close cooperation between companies, higher education and research institutions, as well as state institutions. Dombrovskaya.
Adrian van Den Hoven, CEO of the European Pharmaceutical Organization Medicine for Europe (Latvian: « Medicines for Europe ») at the conference. He emphasized the role of European contexts and the importance of local producers in ensuring critical drugs.
“In recent years, global challenges have also changed the pharmaceutical industry in Europe, encouraging the European Union to look for ways to strengthen the local pharmaceutical sector using the pharmaceutical review and critical drug act. The goal is to reduce strong dependence on Asia while strengthening national security and resilience. Shows the importance of a national strategy for the development of the pharmaceutical sector in cooperation with the European Union.
Medicinal production is important not only for the country’s resistance but also for economic growth – thanks to the high value of the industry and the potential of exports. The Latvian Medicines Industry Strategy for the next ten years provides for development based on the sale of 100 hard -to -mimic products in 100 countries worldwide.
The initiator of the long -term development of the Latvian Medicines Manufacturing Industry Strategy is the Latvian Medical Manufacturers Association. The strategy has been created in cooperation with local companies « Olpha », « Grindeks » and « Pharmidea », the University of Latvia, Riga Stradins University, Riga Technical University and the Latvian Institute of Organic Synthesis.
The mission of the Latvian Medicines Manufacturers Association is to develop the Latvian drug manufacturing and pharmaceutical industry, creating and supplying high quality medications that promote public health and well -being. The association unites Latvia’s largest pharmaceutical companies, which see the implementation of the strategy as an important step towards the breakthrough of industry export and innovation capacity.
